Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: James L. Januzzi Clear advanced filters

  • While fluid restriction is typically recommended for patients with chronic heart failure, this randomized clinical trial showed no difference in health status, as assessed by patient-reported outcomes, between patients recommended to a liberal versus a restrictive fluid regimen over the course of 3 months in an outpatient setting.

    • Job J. Herrmann
    • Hans-Peter Brunner-La Rocca
    • Roland R. J. van Kimmenade
    Research
    Nature Medicine
    Volume: 31, P: 2062-2068

  • The potential of all-virtual clinical trials in cardiology is shown by the CHIEF-HF trial, conducted in the midst of the COVID-19 pandemic, which found that an SGLT2 inhibitor can alleviate heart failure symptoms in patients irrespective of ejection fraction or diabetes status.

    • John A. Spertus
    • Mary C. Birmingham
    • James L. Januzzi
    ResearchOpen Access
    Nature Medicine
    Volume: 28, P: 809-813

  • Schuermans et al. identify a causal relationship between the circulating proteins spondin-1 and atrial fibrillation and SPINT1 and coronary artery disease and show that adding proteomic data improves clinical risk factor-based cardiovascular risk prediction.

    • Art Schuermans
    • Ashley B. Pournamdari
    • Pradeep Natarajan
    ResearchOpen Access
    Nature Cardiovascular Research
    Volume: 3, P: 1516-1530

  • Zhang et al. show increased blood concentration of IGFBP7 in patients and a mouse model with heart failure (HF). IGFBP7 promotes cardiac senescence by stimulating IGF-1R/IRS/AKT-dependent suppression of FOXO3a, and Igfbp7 deficiency or inhibition attenuates cardiac dysfunction in a pressure overload mouse HF model, suggesting that therapeutic targeting of IGFBP7 might be promising for the treatment of HF.

    • Liyong Zhang
    • David Smyth
    • Peter P. Liu
    ResearchOpen Access
    Nature Cardiovascular Research
    Volume: 1, P: 1195-1214

  • Analysis of the results of a large clinical trial, EMPEROR-Preserved, shows that the SGLT2 inhibitor empagliflozin improves outcomes for heart failure patients with either mid-range (41–49%) or preserved (≥50%) ejection fraction, supporting the use of this drug for both categories of patients.

    • Stefan D. Anker
    • Javed Butler
    • Faiez Zannad
    ResearchOpen Access
    Nature Medicine
    Volume: 28, P: 2512-2520

  • Gout is associated with various cardiometabolic–renal comorbidities that increase the risk of mortality. Sodium–glucose cotransporter type 2 (SGLT2) inhibitors show promise in both addressing the symptoms of gout and managing relevant comorbidities to help prevent premature mortality.

    • Chio Yokose
    • Natalie McCormick
    • Hyon K. Choi
    Reviews
    Nature Reviews Rheumatology
    Volume: 20, P: 216-231

  • Heart failure can be broadly divided into two categories: heart failure with preserved ejection fraction and heart failure with reduced ejection fraction (HFrEF). HFrEF accounts for approximately 50% of all cases of heart failure in the United States and is the focus of this Primer by Butler and colleagues.

    • Michelle W. Bloom
    • Barry Greenberg
    • Javed Butler
    Reviews
    Nature Reviews Disease Primers
    Volume: 3, P: 1-19